

Affinité Instruments collaborates closely with the Toronto Recombinant Antibody Centre to validate its flagship SPR instrument

Montréal (QC) and Toronto (ON) – February 1, 2016 – Surface Plasmon Resonance (SPR) is a gold standard technology used in drug development to collect pharmacokinetic information and screen for potential drug. Despite the value provided by the technology to researchers, the expensive cost of acquisition and the complexity of operation of these instruments restrict its usage outside the pharmaceutical industry. Affinité Instrument, a spin-off of the Université de Montréal, has developed innovations which aim at making SPR accessible to academic laboratories and small start-ups. Their flagship device, the portable and 4-channel surface plasmon resonance (P4SPR) instrument, is designed to measure and monitor analytes such as proteins, DNA and even small molecules within complex media (e.g. serum, urine and water). The P4SPR was commercialized for research-based purposes (June 2015) and in September 2015, the Centre for the Commercialization of Antibodies and Biologics in Toronto (CCAB) agreed to validate the P4SPR's analytical performance against a state-of-the-art SPR instrument. *"The P4SPR is ease of use and the accessibility of the instrument allowed it to fit into our regular operations with no down-time, accelerating analysis"* said Dr. James Pan of the CCAB. The P4SPR is currently being tested by a professional team of scientists from the Toronto Recombinant Antibody Centre (TRAC), an antibody discovery centre; results from the on-going validation are expected to be released by February 2016.

For further information with regards to the device, please contact: jf.masson@affiniteinstruments.com or visit the official Affinité Instruments P4SPR product website: <http://affiniteinstruments.com/p4spr-features>.

About CCAB

The Centre for the Commercialization of Antibodies and Biologics is a not-for-profit organization focused on translating research discoveries into products and capturing the tremendous commercial potential arising from the University of Toronto's antibody research and discovery engine: the Toronto Recombinant Antibody Centre (TRAC). The CCAB develops antibodies for any number of applications including: therapeutics, diagnostics, immunosensors, imaging, and research reagents.

More information at <http://www.ccabcanada.com/>

About TRAC

The TRAC was established in 2010 and is housed at the Donnelly Centre for Cellular and Biomolecular Research at the University of Toronto. The TRAC follows the Donnelly Centre philosophy, which is centered around

multidisciplinary research with an emphasis on the development and application of functional genomics technologies. The development and implementation of the TRAC is a concerted effort that is led by Dr. Sachdev Sidhu and involves a group of researchers from the Donnelly Centre and other research centres.

More information at <http://trac.utoronto.ca/>

About P4SPR:

The P4SPR instrument, developed by Affinité Instruments (Montréal Québec), promises to deliver fast, specific and reliable data of specific analytes within complex media such as biological fluids (e.g. blood, serum, urine) and opaque or clear liquids (e.g. milk, juice, water). The compact instrument offers a range of advantages with regards to usage and functionality which includes:

- Low reagent and sample volumes (<100 uL for triplicate measures)
- Real-time monitoring for rapid results
- Extended sample contact time for slow kinetics (>uM)
- Label-free assay

Affinité Contact:

Dr. Jean-François Masson, President

Affinité Instruments

Montréal, QC

+1 (514) 910-4339 | jf.masson@affiniteinstruments.com

Author: Meryam Al-waadh
meryam.al.waadh@mail.utoronto.ca